AMPH - Amphastar P logo

Amphastar P

AMPH

Amphastar Pharmaceuticals develops, manufactures, and sells generic and proprietary injectable, inhalation, and intranasal products. Its portfolio includes treatments for emergencies like hypoglycemia and opioid overdose, along with various APIs and specialty medications.

โš•๏ธ Healthcare NASDAQ Listed 2014 $ USD
$1,000 invested 10 years ago โ†’$1,352today

Score Overview

1 Year
Score
Net Growth-19.93%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth1.41%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.3
Net Growth26.45%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth66.76%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth7x
Net Trend50%
Net Income Consistency
Rev Growth186.10%
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth9x
Net Trend58%
Net Income Consistency
Rev Growth246.87%
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Amphastar P has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. AMPH does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 25.14โ€”
1 Year2025-10-23
$ 24.721.70%
5 Years2021-10-22
$ 19.1931.01%
10 Years2016-10-21
$ 18.5935.23%
All Time2014-06-25
$ 8.75187.31%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 730M$ 78M$ 290M
2025$ 719M$ 98M$ 282M
2024$ 731M$ 159M$ 221M
2023$ 644M$ 137M$ 256M
2022$ 498M$ 91M$ 175M
2021$ 437M$ 62M$ 136M
2020$ 349M$ 1M$ 105M
2019$ 322M$ 48M$ 89M
2018$ 294M-$ 5M$ 89M
2017$ 240M$ 4M$ 68M
2016$ 255M$ 10M$ 72M
2015$ 251M-$ 2M$ 66M
IPO2014$ 210M-$ 10M$ 67M
AMPH - Amphastar P logo

Amphastar P fundamental performance

Between 2020 and 2025, revenue grew from $ 349M to $ 719M and net income grew from $ 1M to $ 98M. Revenue increased in 4 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 251M to $ 719M and net income went from -$ 2M to $ 98M. Revenue increased in 8 of those 10 years; net income in 5.

Amphastar P currently holds a 5-year HDB Score of 6.3 out of 10. How the HDB Score is calculated.

Membership

Explore AMPH with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies